Physician profile
Tara Rower
NPI 1215237961
$16,306.37
in general payments reported to CMS, 2019-2025
30 companies · $3,440 in 2025
The $3,440 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,498 · 2022: $2,566 · 2023: $3,720 · 2024: $4,083 · 2025: $3,440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $637.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,605.74 |
| Education | $636.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,769.67 | 2021-2025 | |
| Janssen Biotech, INC. | $1,630.45 | 2021-2025 | Tremfya, Simponi, Stelara |
| Lilly USA, LLC | $1,327.46 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Pfizer INC. | $1,192.57 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,047.11 | 2021-2025 | Dupixent, Libtayo |
| Ucb, INC. | $1,001.22 | 2021-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $865.76 | 2022-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $840.67 | 2021-2025 | |
| Genzyme Corporation | $791.13 | 2021-2025 | |
| Incyte Corporation | $715.65 | 2021-2025 | Opzelura |
| Amgen INC. | $682.00 | 2021-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $593.84 | 2021-2025 | Ilumya, Absorica Ld, Winlevi |
| Leo Pharma INC. | $509.96 | 2021-2025 | Adbry, Anzupgo |
| Dermavant Sciences, INC. | $474.55 | 2022-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $328.33 | 2023-2025 | Zoryve |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $327.36 | 2021-2024 | Cabtreo, Arazlo |
| Mayne Pharma Commercial LLC | $181.97 | 2023-2025 | |
| Almirall LLC | $180.54 | 2021-2025 | Seysara |
| Genentech USA, INC. | $171.78 | 2021-2025 | Xolair |
| Galderma Laboratories, L.P. | $114.82 | 2021-2025 | Aklief, Nemluvio |
| Sanofi-Aventis U.S. LLC | $99.99 | 2022 | |
| Epi Health, LLC | $97.73 | 2021-2022 | |
| Medimetriks Pharmaceuticals, INC. | $82.24 | 2023 | Neo-Synalar |
| Organon LLC | $72.23 | 2025 | Vtama |
| Vyne Pharmaceuticals INC. | $71.26 | 2021 | |
| Journey Medical Corporation | $46.86 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.58 | 2023-2024 | Cyltezo |
| Dermira, INC. | $32.68 | 2021 | |
| Verrica Pharmaceuticals INC. | $17.06 | 2023 | Ycanth |
| Biofrontera INC. | $4.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tara Rower listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.